selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...